AstraZeneca strengthens Chinese operations and respiratory business with new deals
The company has forged an alliance with Chinese biologics firm WuXi AppTec to produce new biological drugs in the country. AstraZeneca has the option to acquire WuXi AppTec’s
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.